Steris (STE) stock
Health Care · Health Care Equipment
Steris (STE) is a Health Care Equipment company in the Health Care sector, headquartered in Dublin, Ireland. As of October 23, 2026, STE closed at $232.15, a market capitalization of $22.63 billion, the 381st largest company in the S&P 500. The stock trades at 28.4x trailing earnings and 18.8x forward earnings.
- 1-year total return: -3.2% (dividends reinvested)
- 5-year return: +0.7% a year
- 52-week range: $195.14 – $269.44
- Dividend yield: 1.11%, 20 straight years of increases
- FI Handbook report card: C+ across 5 metrics
- 47th largest of 60 Health Care stocks in the S&P 500
STE price chart
1Y price change: -4.0% (price only; total returns below include dividends)
| Total return | 1M | YTD | 1Y | 3Y | 5Y | 10Y | MAX |
|---|---|---|---|---|---|---|---|
| STE | +10.6% | -7.6% | -3.2% | +3.6% | +0.7% | +14.2% | +15.8% |
Dividends reinvested. 3Y and longer are annualized; MAX is annualized since 1992.
STE key statistics
- Market cap
- $22.6B
- #381 in S&P 500
- P/E (TTM)
- 28.4x
- Forward P/E
- 18.8x
- EPS (TTM)
- —
- Revenue (TTM)
- —
- Free cash flow
- $925.6M
- Gross margin
- —
- Operating margin
- —
- Return on equity
- —
- Dividend yield
- 1.11%
- 52-week range
- $195.14 – $269.44
- Beta
- —
- Price / sales
- —
- EV / EBITDA
- —
- Debt / equity
- —
- Employees
- —
STE report card
C+Ten fundamentals graded A to F against fixed thresholds. Not a buy or sell rating.
- Revenue growth——
- Gross margin——
- Operating margin——
- FCF margin——
- Return on equity——
- Net debt / EBITDA0.0xA
- Forward P/E18.8xB
- PEG ratio1.7xC
- Shareholder yield2.2%C
- Share count change / yr2.8%F
STERIS plc (Ireland) financials
Revenue went from $2.6B in fiscal 2017 to $5.9B in fiscal 2026, growing 9.5% a year.
| Fiscal year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.6B | $2.6B | $2.8B | $3.0B | $3.1B | $4.2B | $4.5B | $5.1B | $5.5B | $5.9B |
| Gross profit | $1.0B | $1.1B | $1.2B | $1.3B | $1.3B | $1.9B | $2.0B | $2.2B | $2.4B | $2.6B |
| Operating income | $226.2M | $399.9M | $411.0M | $537.0M | $548.4M | $477.8M | $791.1M | $836.1M | $866.6M | $1.1B |
| Net income | $110.0M | $290.9M | $303.7M | $407.7M | $397.4M | $243.9M | $107.0M | $378.2M | $614.6M | $782.3M |
| EPS (diluted) | $1.28 | $3.39 | $3.55 | $4.76 | $4.63 | $2.48 | $1.07 | $3.81 | $6.20 | $7.93 |
| Free cash flow | $251.2M | $292.2M | $349.8M | $376.0M | $450.4M | $397.2M | $395.0M | $613.0M | $778.0M | $972.4M |
| Buybacks | $97.5M | $65.5M | $81.5M | $51.2M | $14.6M | $55.8M | $308.6M | $11.8M | $211.3M | $235.5M |
| Dividends paid | $93.2M | $102.9M | $112.5M | $123.0M | $133.8M | $163.2M | $183.5M | $200.6M | $219.9M | $241.8M |
| Diluted shares | 86.1M | 85.7M | 85.5M | 85.6M | 85.9M | 98.3M | 100.2M | 99.4M | 99.1M | 98.7M |
Source: SEC filings (10-K XBRL). EPS and share counts are split-adjusted.
What's priced into STE?
A reverse DCF asks what growth the current price requires. With an enterprise value of $22.6B and $925.6M of trailing free cash flow, STERIS plc (Ireland) needs to grow free cash flow about 15.6% a year for ten years (fading to 3.0% terminal growth) to earn a 10% annual return. For context, free cash flow grew 16.6% a year over the last five years.
P/E ratio history
Current 29.3x vs. median 46.6x (10th–90th percentile 33.6x–158.4x).
A model, not a forecast or advice. Small changes in assumptions move the answer a lot.
STE dividend
- Dividend yield
- 1.11%
- Annual dividend
- $2.58
- Years of increases
- 20
- 5-yr dividend growth
- 2.8%
- per year
- Payments per year
- 4
Regular dividends per share by calendar year; special dividends excluded. Current year omitted until complete.
STE analyst price targets
8 analysts' average 12-month target is $260.71 (+12% vs. $232.15). Targets range from $232.00 to $275.00. 63% rate it a buy.
STE earnings
Next report: November 4, 2026. STERIS plc (Ireland) has beaten EPS estimates 1 quarters in a row. Last quarter's revenue was $1.5B (+7% year over year).
| Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|
| Aug 5, 2026 | $2.49 | $2.59 | +3.9% |
| May 11, 2026 | $2.85 | $2.83 | -0.7% |
| Feb 4, 2026 | $2.53 | $2.53 | -0.1% |
| Nov 5, 2025 | $2.35 | $2.47 | +5.0% |
| Aug 6, 2025 | $2.26 | $2.34 | +3.4% |
| May 14, 2025 | $2.60 | $2.74 | +5.4% |
| Feb 5, 2025 | $2.32 | $2.32 | -0.1% |
| Nov 6, 2024 | $2.13 | $2.14 | +0.4% |
Stocks like STE
| Name | Today | 1Y | Mkt cap | P/E | |
|---|---|---|---|---|---|
 ABT Abbott Laboratories | +1.16% | -16% | $179.4B | 38.6x | Compare |
 ISRG Intuitive Surgical | +1.90% | -18% | $159.8B | 54.7x | Compare |
 MDT Medtronic plc. | -1.22% | +5% | $122.0B | 23.4x | Compare |
 SYK Stryker | +0.02% | -19% | $117.8B | 31.8x | Compare |
 BSX Boston Scientific | -0.70% | -55% | $66.2B | 18.5x | Compare |
 BDX Becton, Dickinson and | -0.75% | +39% | $54.2B | 46.3x | Compare |
 EW Edwards Lifesciences Corporatio | -1.13% | +16% | $51.3B | 53.0x | Compare |
 IDXX IDEXX Laboratories | -1.13% | -12% | $44.1B | 39.4x | Compare |
STE news
- Earnings Preview: What To Expect From STERIS' Report · Oct 23, 2026
- STERIS to Host a Conference Call for Fiscal 2027 Second Quarter on November 5, 2026 · Oct 20, 2026
- Reasons to Add STE Stock to Your Portfolio Right Now · Oct 16, 2026
- Steris inks $2.1B Xodus buyout to expand consumables portfolio · Oct 13, 2026
- Steris outlays $2.1bn to acquire Xodus Medical · Oct 13, 2026
STE stock FAQ
What is STE's market cap?
Steris's market capitalization is $22.63 billion as of October 23, 2026, ranking 381st in the S&P 500.
What is STE's P/E ratio?
STE trades at a trailing price-to-earnings ratio of 28.4x and a forward P/E of 18.8x. Its median P/E over the period we track is 46.6x.
Does STE pay a dividend?
Yes. Steris pays $2.58 per share a year, a 1.11% yield. It has raised its dividend 20 years in a row. Dividends grew 2.8% a year over the last five years.
How much has STE stock returned?
Including reinvested dividends, STE returned -3.2% over one year, +0.7% a year over five years, +14.2% a year over ten years through October 23, 2026.
Is STE stock overvalued?
At today's price, a reverse discounted cash flow model (10% discount rate, 3% terminal growth) implies Steris must grow free cash flow about 16% a year for the next decade. Its free cash flow grew 17% a year over the last five years. Whether that is achievable decides if the stock is cheap or expensive. This is a model, not advice.
What is the STE price target?
8 analysts cover STE with an average 12-month price target of $260.71, +12% from the current price. 62% of them rate it a buy.
When does STE report earnings?
Steris is expected to report earnings on November 4, 2026. It has beaten EPS estimates 1 quarters in a row.
Sources: SEC EDGAR filings, Yahoo Finance market data (delayed), FI Handbook calculations. Last close October 23, 2026. Methodology